Repligen Stock

Repligen FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Repligen (RGEN) as of Sep 9, 2026 is 192.04 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -558.47 % — a change of -134.39% (higher).

FCF Conversion

192.04 %

YoY

-134.39%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Repligen is 2026 192.04 % . FCF Conversion Rate (FCF/EBITDA) of Repligen was 2025 -558.47 % . It decreases by -134.39% higher compared to the previous year.

The Repligen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
112.73 USD
Jan 1, 2019
205.79 USD
Jan 1, 2020
60.54 USD
Jan 1, 2021
40.48 USD
Jan 1, 2022
20.83 USD
Jan 1, 2023
180.22 USD
Jan 1, 2024
-558.47 USD
Jan 1, 2025
192.04 USD
The Repligen FCF Conversion history
YEARFCF ConversionYoY
192.04 %-134.39%
-558.47 %-409.88%
180.22 %+765.15%
20.83 %-48.54%
40.48 %-33.15%
60.54 %-70.58%
205.79 %+82.55%
112.73 %+166.43%
42.31 %+54.65%
27.36 %-79.42%
132.96 %-15.12%
156.65 %
Access this data via the Eulerpool API

Repligen Stock analysis

What does Repligen do? Repligen Corp is an American company that was founded in 1981 and is headquartered in Waltham, Massachusetts. The company is a leading provider of products for the biopharmaceutical industry. It offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The history of Repligen Corp begins in the 1980s when the company was originally founded to produce human proteins for medical purposes. Over the years, the company expanded its business and focused on the production of purification solutions for the biopharmaceutical industry. Today, Repligen is an established company in this field and serves customers around the world. Business model: Repligen Corp is a leading provider of products and services for the biopharmaceutical industry. The company focuses on the development and manufacturing of products for the purification of proteins and antibodies. These products are used by biotech and pharmaceutical customers to improve the effectiveness and safety of their products in the clinical development process. Repligen Corp is generally able to achieve good prices for its products as they are high-quality products for a high-priced industry. The company is also interested in introducing new products to the market and expanding its customer base. Various divisions: Repligen Corp offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The company is divided into various divisions, including: 1. Chromaflow: Repligen's Chromaflow products offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. These products enable customers to test and develop their products faster and more effectively. 2. Protein A Adsorbent Resin: Repligen Corp offers a Protein A Adsorbent Resin used in biotherapy. It allows for highly efficient purification of therapeutics produced using Protein A. 3. Alternating Tangential Flow (ATF) Systems: Repligen's ATF system enables continuous cell culture of proteins and antibodies. This facilitates the production of biopharmaceutical products and shortens development time. 4. Process Analytical Technology (PAT): Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. It improves process control and reduces the risk of errors and failures. 5. Filtration products: Repligen's filtration products include disposable filters and microfiltration membranes. These products are used by customers in the biopharmaceutical industry for the purification of biological products. Products: Repligen Corp offers a wide range of innovative products and services to support the development of biological drugs. Here are some of the products offered by Repligen Corp: 1. Protein A Adsorbent Resin: This product is used in biotherapy and the biopharmaceutical industry to enable highly efficient purification of therapeutics produced using Protein A. 2. Alternating Tangential Flow (ATF) Systems: This system enables continuous cell culture of proteins and antibodies. It facilitates the production of biopharmaceutical products and shortens development time. 3. Chromaflow products: They offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. 4. PAT systems: Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. 5. Filtration products: Repligen's filtration products include disposable filters and membranes. These products are used by customers in the biopharmaceutical industry to purify biological products. In summary, Repligen Corp is an established company that focuses on the development and production of products and services for the biopharmaceutical industry. The company offers a wide range of innovative products that contribute to the acceleration and improvement of the development of biological drugs. With its long history and established reputation as a leading provider, Repligen Corp is a significant player in the biopharmaceutical industry. Repligen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Repligen stock

FCF Conversion Rate (FCF/EBITDA) of Repligen is 192.04 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Repligen changed from -558.47 % to 192.04 %, representing a -134.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Repligen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Repligen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Repligen

All Key Metrics — Repligen